Skip to content

Azenta AZTA Multiomics — Segment adjusted operating loss

Similar metrics at other companies

Mirion Technologies logo
MIRMedical Segment — Adjusted Income Loss From Operations
-$25.4M-3.7%
John Wiley & Sons, Inc. logo
WLYBAdjusted Operating Income (Loss) by segment
$148.37M+10.8%
Assured Guaranty logo
AGOAsset Management — Segment adjusted operating income (loss)
$44M+267%
eXp World Holdings, Inc. Common Stock logo
AGNTAll Other Segments — Operating Income
-$194K+88.2%
Itron logo
ITRIOutcomes — Adjusted segment operating income (loss)
$22.36M+56.0%
Science Applications International Corporation logo
SAICCorporate Segment — Adjusted operating income (loss)
$7M+178%

Other financials

Income statement

See full
Revenue$144.8M+1.0%
Gross profit$62.0M-1.2%
Operating income-$165.8M-811%
Net income-$160.8M-237%
EPS (diluted)-$3.49-236%

Balance sheet

See full
Cash & equivalents$125.2M
Total debt$55.7M
Total equity$1.6B-8.3%
Total assets$1.9B

Cash flow

See full
Operating cash flow$13.5M-6.2%
CapEx$7.4M-0.1%
Free cash flow$6.1M-12.7%

Valuation

See full
Market cap$1.1B-16.3%
Enterprise value$1.03B
P/S1.8×-0.2×

Profitability

See full
Gross margin40%-1.0pp
Operating margin-31.6%-59.7pp
Net margin-29.1%-80.7pp
FCF margin8.6%

Returns & leverage

See full
Return on equity-10.7%-22.4pp
Debt / equity
Current ratio2.8×

Where this comes from

Reported directly by Azenta in its filing.

Tagged under the XBRL concept azta:OperatingIncomeLossAdjusted.

The official record: Azenta’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Azenta's multiomics — segment adjusted operating loss.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Azenta's multiomics — segment adjusted operating loss?
Azenta (AZTA) reported multiomics — segment adjusted operating loss of -$10.07M in Q1 2026.
What does multiomics — segment adjusted operating loss mean?
A non-GAAP measure representing the operating loss of the Multiomics segment after adjusting for specific items like stock-based compensation, amortization, or restructuring costs. This metric provides a clearer view of the segment's core operational performance by removing non-cash or non-recurring accounting impacts. It is used to evaluate the underlying profitability trajectory of the business unit.